Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: a break of intestinal insulin resistance?

J Hepatol. 2010 Jun;52(6):952-3. doi: 10.1016/j.jhep.2010.02.004. Epub 2010 Mar 15.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Acarbose / administration & dosage*
  • Anticholesteremic Agents / administration & dosage*
  • Azetidines / administration & dosage*
  • Drug Therapy, Combination
  • Ezetimibe
  • Fatty Liver / drug therapy
  • Fatty Liver / metabolism
  • Fatty Liver / prevention & control*
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Insulin Resistance*

Substances

  • Anticholesteremic Agents
  • Azetidines
  • Hypoglycemic Agents
  • Ezetimibe
  • Acarbose